Event chart REGENERON PHARMACEUTICALS, INC. |
|
|
Upcoming events on REGENERON PHARMACEUTICALS, INC. |
|
02/03/23 | | FY 2022 Earnings Release |
02/03/23 | 08:30am | | FY 2022 Earnings Call |
05/04/23 | | Q1 2023 Earnings Release (Projected) |
08/03/23 | | Interim 2023 Earnings Release (Projected) |
11/07/23 | | Q3 2023 Earnings Release (Projected) |
02/08/24 | | FY 2023 Earnings Release (Projected) |
|
Past events on REGENERON PHARMACEUTICALS, INC. |
|
01/09/23 | 12:00pm | | JP Morgan Healthcare Conference |
12/14/22 | 08:30am | | American Society of Hematology Meeting |
12/13/22 | | American Society of Hematology Meeting - Abstract 3652 |
12/13/22 | | American Society of Hematology Meeting - Abstract #3992 |
12/12/22 | 05:30pm | | American Society of Hematology Meeting - Abstract #949 |
12/12/22 | | American Society of Hematology Meeting - Abstract #4873 |
12/12/22 | | American Society of Hematology Meeting - Abstract 4896 |
12/12/22 | | American Society of Hematology Meeting - Abstract #4551 |
12/12/22 | | American Society of Hematology Meeting - Abstract #4555 |
12/12/22 | | American Society of Hematology Meeting - Abstract #3601 |
|
Past dividends on REGENERON PHARMACEUTICALS, INC. |
|
- No events available -
|
|
Fiscal Period : December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
Sales M $ |
Released Forecast Spread | 5 872 5 788 1,5% | 6 711 6 520 2,9% | 7 863 7 816 0,61% | 8 497 8 494 0,04% | 16 072 15 679 2,5% | 11 850 |
Operating income (EBITDA) M $ |
Released Forecast Spread | 2 732 2 658 2,8% | 3 110 2 959 5,1% | 3 420 3 610 -5,3% | 4 245 4 158 2,1% | 9 835 9 709 1,3% | 6 161 |
Operating profit (EBIT) M $ |
Released Forecast Spread | 2 080 2 094 -0,70% | 2 534 2 424 4,5% | 2 210 2 285 -3,3% | 3 577 3 485 2,6% | 8 947 9 034 -0,96% | 5 561 |
Pre-Tax Profit (EBT) M $ |
Released Forecast Spread | 2 079 2 075 0,16% | 2 554 2 543 0,39% | 2 429 2 308 5,3% | 3 810 3 582 6,4% | 9 326 9 442 -1,2% | 4 812 |
Net income M $ |
Released Forecast Spread | 1 199 1 438 -17% | 2 444 2 257 8,3% | 2 116 1 998 5,9% | 3 513 3 160 11% | 8 075 8 014 0,77% | 4 166 |
EPS $ |
Released Forecast Spread | 10,3 12,6 -18% | 21,3 19,7 7,9% | 18,5 17,6 4,7% | 30,5 28,0 9,0% | 72,0 71,1 1,2% | 36,3 | Announcement Date | 02/08/2018 | 02/06/2019 | 02/06/2020 | 02/05/2021 | 02/04/2022 | - |
|
|
Fiscal Period : December | 2020 Q3 | 2020 Q4 | 2021 Q1 | 2021 Q2 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 |
Sales M $ |
Released Forecast Spread | 2 294 2 085 10% | 2 423 2 402 0,88% | 2 529 2 561 -1,3% | 5 139 3 972 29% | 3 453 2 800 23% | 4 952 4 526 9,4% | 2 965 2 690 10% | 2 857 2 797 2,1% | 2 936 2 870 2,3% | 3 113 | 3 028 | 3 103 | 3 207 | 3 286 |
Operating income (EBITDA) M $ |
Released Forecast Spread | 1 112 907 23% | 1 229 1 194 2,9% | 1 311 1 118 17% | 3 564 2 813 27% | 2 057 1 314 57% | 2 903 2 564 13% | 1 558 1 376 13% | 1 344 1 220 10% | 1 488 1 344 11% | 1 336 | 1 619 | 1 590 | 1 763 | 1 936 |
Operating profit (EBIT) M $ |
Released Forecast Spread | 1 053 850 24% | 1 167 991 18% | 1 113 1 040 7,0% | 3 347 1 949 72% | 1 847 1 278 45% | 2 640 2 601 1,5% | 1 483 1 273 17% | 1 285 1 124 14% | 1 413 1 313 7,6% | 1 344 | 1 363 | 1 396 | 1 375 | 1 538 |
Pre-Tax Profit (EBT) M $ |
Released Forecast Spread | 998 861 16% | 1 225 898 36% | 1 253 1 079 16% | 3 753 1 872 100% | 1 817 1 392 30% | 2 503 2 649 -5,5% | 1 061 1 185 -10% | 963 1 116 -14% | 1 510 984 53% | 1 154 | 1 062 | 1 062 | 1 295 | 1 533 |
Net income M $ |
Released Forecast Spread | 842 713 18% | 1 149 802 43% | 1 115 953 17% | 3 099 1 653 88% | 1 632 1 152 42% | 2 229 2 108 5,7% | 974 1 038 -6,2% | 852 794 7,4% | 1 316 845 56% | 1 060 | 879 | 957 | 1 039 | 1 122 |
EPS $ |
Released Forecast Spread | 7,39 6,35 16% | 10,2 7,11 44% | 10,1 8,31 21% | 28,0 16,0 75% | 14,3 10,7 34% | 19,7 19,4 1,3% | 8,61 8,77 -1,9% | 7,47 7,38 1,3% | 11,7 7,93 47% | 9,23 | 8,34 | 8,83 | 9,17 | 9,51 | Announcement Date | 11/05/2020 | 02/05/2021 | 05/06/2021 | 08/05/2021 | 11/04/2021 | 02/04/2022 | 05/04/2022 | 08/03/2022 | 11/03/2022 | - | - | - | - | - | |
|
|
Upcoming sector events for REGENERON PHARMACEUTICALS, INC. |
|
|
|
Past sector events for REGENERON PHARMACEUTICALS, INC. |
|
|
|
|
|
|
U.S. to announce list of drugs for pricing negotiations Sept. 1 |
Net sales (Year) - Rate of surprise
EPS (Year) - Rate of surprise
Net sales (Quarter) - Rate of surprise
EPS (Quarter) - Rate of surprise
|